Skip to Content

Gamunex-C Approval History

  • FDA approved: Yes (First approved October 13th, 2010)
  • Brand name: Gamunex-C
  • Generic name: immune globulin intravenous and subcutaneous
  • Dosage form: Injection
  • Company: Talecris Biotherapeutics, Inc.
  • Treatment for: Primary Immunodeficiency Syndrome

Gamunex-C (immune globulin intravenous and subcutaneous) is indicated for the treatment of primary immunodeficiency (PI).

Development History and FDA Approval Process for Gamunex-C

Oct 14, 2010Approval Talecris Biotherapeutics Receives FDA Approval for Gamunex-C

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.